Developer docs
API playgroundTry for free, no card

Search company profiles

Formation Bio

Full company profile

uuid0000exx

Namestring
Formation Bio
Legal namestring
Formation Bio
Websiteurl
formation.bio
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Formation Bio is an AI-native drug development company that acquires clinical-stage pharmaceutical assets from pharma companies, universities, and biotech firms and develops them in-house using a proprietary technology platform, then either out-licenses completed programs to larger pharmaceutical partners or advances them toward commercialization. The company is headquartered in New York City with additional hubs in Boston, the San Francisco Bay Area, and North Carolina's Research Triangle, operating with a deliberately compact 101–250-person cross-functional team that bridges pharma development and software engineering. Its current pipeline spans five assets across therapeutic areas including autoimmune disease, dermatology, CNS disorders, inflammatory bowel disease, and osteoarthritis.

The company's core technology stack is organized into six integrated modules: Delphi (clinical trial success prediction via multi-agent architecture), Atlas (asset sourcing and screening across dozens of upstream sources), Forge (AI-driven trial design evaluated across thousands of configurations trained on 300,000+ precedent trials), Apollo (trial execution currently managing 142 active sites), ARK (an MCP-based AI operating system connecting 80+ internal systems to OpenAI, Anthropic, and Google models), and a Data Platform unifying 720,000+ clinical trials, 150M+ real-world patient records, 4.6M+ scientific papers, and 290K+ deals. Muse, a GenAI patient recruitment tool, sits on top of Apollo. The platform is operated by a team whose leadership includes alumni of Pfizer, Allergan, Tessera Therapeutics, BenevolentAI, and Oscar Health, and whose advisors have collectively worked on 45+ approved drugs.

Formation Bio generates revenue through asset licensing and development partnerships, including upfront payments, development/regulatory/commercial milestones, and tiered royalties. Disclosed deal value includes a $630M Sanofi agreement for gusacitinib, a $605M-plus Lynk Pharmaceuticals transaction for the TYK2 inhibitor BLKR201, and a reported ~$2.5B from sales of two AI-optimized drug compounds. The company is privately held, has raised over $615M from investors including Andreessen Horowitz, Sequoia, Thrive Capital, Sanofi, and Sam Altman at a $1.8B valuation, and operates three wholly-owned asset subsidiaries (Bleecker Bio, High Line Bio, Libertas Bio) to ring-fence specific programs.

Short descriptiontext

Formation Bio is an AI-native drug development company that acquires clinical-stage pharmaceutical assets from pharma, biotech, and academic sources and develops them in-house using a proprietary six-module AI platform before out-licensing or commercializing the programs for large pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical drug development, AI drug discovery, pharmaceutical asset licensing, clinical trial technology, biotech asset acquisition
Industry3 codes
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI-Driven Pharmaceutical Drug Development
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Asset Licensing and Development
TypeLicensing Royalties
Description

Acquire clinical-stage drug candidates and develop them using proprietary AI platform. Realize value through out-licensing deals with milestone payments, royalties, or direct asset sales upon reaching development inflection points. Revenue comes from upfront payments, development/regulatory/commercial milestones, and tiered royalties.

formation.bio
2Asset Sales
TypeTransaction Fee
Description

Development partnerships where Formation Bio sells completed or advanced drug compounds to pharmaceutical partners. Examples include $630M Sanofi licensing deal and reportedly generated ~$2.5B from selling two AI-optimized drug compounds.

forbes.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Formation Bio acquires clinical-stage drug candidates from pharma companies, universities, and biotech firms and develops them in-house using its proprietary AI-native drug development platform. The company then monetizes these assets through out-licensing deals, milestone payments, royalties, or asset sales to larger pharmaceutical partners. Current pipeline assets include BLKR201 (Phase 1), Sprifermin (Phase 2), Gusacitinib (Phase 3, licensed to Sanofi), RVW101 (Phase 1), and KMR301 (preclinical).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 50% reduction in clinical trial timelines through AI optimization
+3 more records
Product overview1 text field

Formation Bio is an AI-native pharma company operating a tech-driven drug development platform. The core platform consists of six interconnected modules: Delphi (predictive intelligence), Atlas (drug hunting), Forge (trial design), Apollo (trial execution), ARK (AI operating system), and the Data Platform. Muse is a GenAI-powered patient recruitment tool integrated with Apollo. The company acquires and develops clinical-stage drug candidates through subsidiaries including Bleecker Bio, High Line Bio, and Libertas Bio. Current pipeline includes BLKR201 (Phase 1 CNS TYK2 inhibitor), Sprifermin (Phase 2 osteoarthritis), Gusacitinib (Phase 3, licensed to Sanofi for chronic hand eczema), RVW101 (Phase 1 anti-CD226 antibody), and KMR301 (preclinical miR-124 inducer).

Product and service5 records
1BLKR201 (formerly LNK01006)
CategoryDrug Candidate (TYK2 Inhibitor)
Description

CNS-penetrant TYK2 inhibitor in Phase 1 clinical development for autoimmune and inflammatory conditions affecting the central nervous system; licensed from Lynk Pharmaceuticals and developed within the Bleecker Bio subsidiary.

2Sprifermin
CategoryDrug Candidate (FGF18 Growth Factor)
Description

Recombinant human fibroblast growth factor 18 (FGF18) in Phase 2 for knee osteoarthritis, a degenerative joint disease with no approved disease-modifying therapies; developed within the High Line Bio subsidiary.

3Gusacitinib
CategoryDrug Candidate (SYK/JAK Inhibitor)
Description

SYK/JAK inhibitor licensed to Sanofi in Phase 3 development for chronic hand eczema, an underserved condition impacting up to 10% of adults with no approved US treatments.

4RVW101
CategoryDrug Candidate (Anti-CD226 Antibody)
Description

Anti-CD226 monoclonal antibody in development for ulcerative colitis, a chronic inflammatory bowel disease affecting approximately 5 million people globally.

5KMR301
CategoryDrug Candidate (miR-124 Inducer)
Description

Oral small molecule miR-124 inducer in preclinical development for autoimmune disease; miR-124 is an anti-inflammatory microRNA reduced in multiple immunology and inflammatory diseases.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1CTFH (Clinical Trial Facility/Hospital)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Licensed miR-124 activator for autoimmune diseases. Partnership to develop microRNA-based therapy targeting inflammatory diseases.

formation.bio
2Lynk Pharmaceuticals
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-10
Description

Exclusive development and licensing agreement for CNS-penetrant TYK2 inhibitor LNK01006 (now BLKR201). Deal exceeds $605M including upfront payment, equity stake, milestones, and royalties. Formation Bio formed Bleecker Bio subsidiary for development. First patient dosed June 2026 in Phase 1 trial.

fiercebiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-21
Description

Three-way AI collaboration with OpenAI and Sanofi to develop AI-powered software for drug development. Sanofi invested $372M in Formation Bio's Series D. Sanofi also licensed gusacitinib for up to $630M. Sanofi Ventures committed $1.4B fund with $625M focused on AI-driven drug discovery investments.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-05-21
Description

Three-way collaboration with Sanofi and Formation Bio to fine-tune AI models on proprietary pharmaceutical data for drug development applications. Sam Altman personally invested and serves as backer.

Strategic tierCoreTypeTechnology or Integration
Description

Formation Bio reportedly in $2B deal with Eli Lilly. Major pharmaceutical partnership for drug development.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-native drug discovery and development company combining high-throughput biology with machine learning to advance clinical programs. Directly comparable as a tech-native pharma pursuing AI-driven development acceleration, though Recursion emphasizes discovery while Formation Bio emphasizes clinical execution.

TypeDirect peer
Description

Machine learning-driven drug discovery and development company. Comparable in applying AI/ML to pharma R&D and in operating at the intersection of technology and life sciences with a venture-backed business model.

TypeDirect peer
Description

AI-driven drug discovery company using knowledge graphs and machine learning to identify novel targets and advance clinical programs. Comparable AI-native approach to pharma development; Formation Bio's CTO previously served as CTO at BenevolentAI.

TypeDirect peer
Description

AI-driven precision medicine company focused on small molecule drug discovery and development. Comparable in using AI to accelerate drug development and in pursuing licensing/partnering business models with pharma.

TypeDirect peer
Description

Computational chemistry and AI-driven drug discovery platform serving both internal programs and external pharma partners. Comparable in providing AI/computational tools for pharma development with a hybrid business model.

6Isomorphic Labs
TypeDirect peer
Description

Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction and AI capabilities to pharmaceutical R&D. Comparable as a well-capitalized AI-native pharma pursuing end-to-end drug development.

TypeDirect peer
Description

AI and quantum physics-driven drug discovery company combining computational platforms with wet-lab validation. Comparable in applying advanced AI/ML techniques to accelerate small molecule and biologic drug development.

TypeEmerging player
Description

AI biotech applying federated learning and AI to drug discovery and clinical development, with a particular emphasis on real-world patient data. Comparable in leveraging AI for clinical insights and pharma partnership models.

TypeBroad incumbent
Description

Large pharmaceutical company that is both a partner (reported ~$2B deal) and increasingly developing in-house AI drug development capabilities. Relevant as a strategic counterparty and as a benchmark for incumbent AI investment in pharma.

TypeBroad incumbent
Description

Major pharmaceutical partner and investor that licensed gusacitinib for $630M+ and led the Series D. Comparable as a strategic pharma partner pursuing AI-driven drug development, both as a collaboration partner and competitive incumbent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration9 records

Each record includes

Title, Type, Description, Source

AI capability11 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Formation Bio

AI-Driven Pharmaceutical Drug Developmentformation.bio

Formation Bio is an AI-native drug development company that acquires clinical-stage pharmaceutical assets from pharma, biotech, and academic sources and develops them in-house using a proprietary six-module AI platform before out-licensing or commercializing the programs for large pharmaceutical partners.

What Formation Bio does

Formation Bio is an AI-native drug development company that acquires clinical-stage pharmaceutical assets from pharma companies, universities, and biotech firms and develops them in-house using a proprietary technology platform, then either out-licenses completed programs to larger pharmaceutical partners or advances them toward commercialization. The company is headquartered in New York City with additional hubs in Boston, the San Francisco Bay Area, and North Carolina's Research Triangle, operating with a deliberately compact 101–250-person cross-functional team that bridges pharma development and software engineering. Its current pipeline spans five assets across therapeutic areas including autoimmune disease, dermatology, CNS disorders, inflammatory bowel disease, and osteoarthritis.

The company's core technology stack is organized into six integrated modules: Delphi (clinical trial success prediction via multi-agent architecture), Atlas (asset sourcing and screening across dozens of upstream sources), Forge (AI-driven trial design evaluated across thousands of configurations trained on 300,000+ precedent trials), Apollo (trial execution currently managing 142 active sites), ARK (an MCP-based AI operating system connecting 80+ internal systems to OpenAI, Anthropic, and Google models), and a Data Platform unifying 720,000+ clinical trials, 150M+ real-world patient records, 4.6M+ scientific papers, and 290K+ deals. Muse, a GenAI patient recruitment tool, sits on top of Apollo. The platform is operated by a team whose leadership includes alumni of Pfizer, Allergan, Tessera Therapeutics, BenevolentAI, and Oscar Health, and whose advisors have collectively worked on 45+ approved drugs.

Formation Bio generates revenue through asset licensing and development partnerships, including upfront payments, development/regulatory/commercial milestones, and tiered royalties. Disclosed deal value includes a $630M Sanofi agreement for gusacitinib, a $605M-plus Lynk Pharmaceuticals transaction for the TYK2 inhibitor BLKR201, and a reported ~$2.5B from sales of two AI-optimized drug compounds. The company is privately held, has raised over $615M from investors including Andreessen Horowitz, Sequoia, Thrive Capital, Sanofi, and Sam Altman at a $1.8B valuation, and operates three wholly-owned asset subsidiaries (Bleecker Bio, High Line Bio, Libertas Bio) to ring-fence specific programs.

Formation Bio firmographics

Firmographics
Name
Formation Bio
Legal name
Formation Bio
Website
https://formation.bio
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Formation Bio is an AI-native drug development company that acquires clinical-stage pharmaceutical assets from pharma, biotech, and academic sources and develops them in-house using a proprietary six-module AI platform before out-licensing or commercializing the programs for large pharmaceutical partners.
Ownership category
akta.pro rank

Formation Bio industry classification

Industry
Product category
AI-Driven Pharmaceutical Drug Development
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)

Keywords

  • Clinical drug development
  • AI drug discovery
  • Pharmaceutical asset licensing
  • Clinical trial technology
  • Biotech asset acquisition

Where Formation Bio is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Formation Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Asset Licensing and Development: Acquire clinical-stage drug candidates and develop them using proprietary AI platform. Realize value through out-licensing deals with milestone payments, royalties, or direct asset sales upon reaching development inflection points. Revenue comes from upfront payments, development/regulatory/commercial milestones, and tiered royalties.
  2. Asset Sales: Development partnerships where Formation Bio sells completed or advanced drug compounds to pharmaceutical partners. Examples include $630M Sanofi licensing deal and reportedly generated ~$2.5B from selling two AI-optimized drug compounds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Formation Bio product offering

Product offering

Core offering

Formation Bio acquires clinical-stage drug candidates from pharma companies, universities, and biotech firms and develops them in-house using its proprietary AI-native drug development platform. The company then monetizes these assets through out-licensing deals, milestone payments, royalties, or asset sales to larger pharmaceutical partners. Current pipeline assets include BLKR201 (Phase 1), Sprifermin (Phase 2), Gusacitinib (Phase 3, licensed to Sanofi), RVW101 (Phase 1), and KMR301 (preclinical).

Product overview

Formation Bio is an AI-native pharma company operating a tech-driven drug development platform. The core platform consists of six interconnected modules: Delphi (predictive intelligence), Atlas (drug hunting), Forge (trial design), Apollo (trial execution), ARK (AI operating system), and the Data Platform. Muse is a GenAI-powered patient recruitment tool integrated with Apollo. The company acquires and develops clinical-stage drug candidates through subsidiaries including Bleecker Bio, High Line Bio, and Libertas Bio. Current pipeline includes BLKR201 (Phase 1 CNS TYK2 inhibitor), Sprifermin (Phase 2 osteoarthritis), Gusacitinib (Phase 3, licensed to Sanofi for chronic hand eczema), RVW101 (Phase 1 anti-CD226 antibody), and KMR301 (preclinical miR-124 inducer).

Differentiator

Problem solved

Functional benefit

Products and services

  • BLKR201 (formerly LNK01006) CNS-penetrant TYK2 inhibitor in Phase 1 clinical development for autoimmune and inflammatory conditions affecting the central nervous system; licensed from Lynk Pharmaceuticals and developed within the Bleecker Bio subsidiary.
  • Sprifermin Recombinant human fibroblast growth factor 18 (FGF18) in Phase 2 for knee osteoarthritis, a degenerative joint disease with no approved disease-modifying therapies; developed within the High Line Bio subsidiary.
  • Gusacitinib SYK/JAK inhibitor licensed to Sanofi in Phase 3 development for chronic hand eczema, an underserved condition impacting up to 10% of adults with no approved US treatments.
  • RVW101 Anti-CD226 monoclonal antibody in development for ulcerative colitis, a chronic inflammatory bowel disease affecting approximately 5 million people globally.
  • KMR301 Oral small molecule miR-124 inducer in preclinical development for autoimmune disease; miR-124 is an anti-inflammatory microRNA reduced in multiple immunology and inflammatory diseases.

Quantifiable outcome

  • 50% reduction in clinical trial timelines through AI optimization
  • +3 more outcomes

Companies that use Formation Bio

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Formation Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability11 records

Feature8 records

Formation Bio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • CTFH (Clinical Trial Facility/Hospital)minorStrategic or Co-development Partner · 29 January 2026Licensed miR-124 activator for autoimmune diseases. Partnership to develop microRNA-based therapy targeting inflammatory diseases.
  • Lynk PharmaceuticalscoreTechnology or Integration · 10 December 2025Exclusive development and licensing agreement for CNS-penetrant TYK2 inhibitor LNK01006 (now BLKR201). Deal exceeds $605M including upfront payment, equity stake, milestones, and royalties. Formation Bio formed Bleecker Bio subsidiary for development. First patient dosed June 2026 in Phase 1 trial.
  • SanoficoreStrategic or Co-development Partner · 21 May 2024Three-way AI collaboration with OpenAI and Sanofi to develop AI-powered software for drug development. Sanofi invested $372M in Formation Bio's Series D. Sanofi also licensed gusacitinib for up to $630M. Sanofi Ventures committed $1.4B fund with $625M focused on AI-driven drug discovery investments.
  • OpenAIcoreTechnology or Integration · 21 May 2024Three-way collaboration with Sanofi and Formation Bio to fine-tune AI models on proprietary pharmaceutical data for drug development applications. Sam Altman personally invested and serves as backer.
  • Eli LillycoreTechnology or IntegrationFormation Bio reportedly in $2B deal with Eli Lilly. Major pharmaceutical partnership for drug development.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Formation Bio competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-native drug discovery and development company combining high-throughput biology with machine learning to advance clinical programs. Directly comparable as a tech-native pharma pursuing AI-driven development acceleration, though Recursion emphasizes discovery while Formation Bio emphasizes clinical execution.
  • Insitro: Machine learning-driven drug discovery and development company. Comparable in applying AI/ML to pharma R&D and in operating at the intersection of technology and life sciences with a venture-backed business model.
  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and machine learning to identify novel targets and advance clinical programs. Comparable AI-native approach to pharma development; Formation Bio's CTO previously served as CTO at BenevolentAI.
  • Exscientia: AI-driven precision medicine company focused on small molecule drug discovery and development. Comparable in using AI to accelerate drug development and in pursuing licensing/partnering business models with pharma.
  • Schrödinger: Computational chemistry and AI-driven drug discovery platform serving both internal programs and external pharma partners. Comparable in providing AI/computational tools for pharma development with a hybrid business model.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction and AI capabilities to pharmaceutical R&D. Comparable as a well-capitalized AI-native pharma pursuing end-to-end drug development.
  • XtalPi: AI and quantum physics-driven drug discovery company combining computational platforms with wet-lab validation. Comparable in applying advanced AI/ML techniques to accelerate small molecule and biologic drug development.

Emerging players

  • Owkin: AI biotech applying federated learning and AI to drug discovery and clinical development, with a particular emphasis on real-world patient data. Comparable in leveraging AI for clinical insights and pharma partnership models.

Broad incumbents

  • Eli Lilly (Lilly Catalyze360 / TuneLab): Large pharmaceutical company that is both a partner (reported ~$2B deal) and increasingly developing in-house AI drug development capabilities. Relevant as a strategic counterparty and as a benchmark for incumbent AI investment in pharma.
  • Sanofi: Major pharmaceutical partner and investor that licensed gusacitinib for $630M+ and led the Series D. Comparable as a strategic pharma partner pursuing AI-driven drug development, both as a collaboration partner and competitive incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Formation Bio social profiles

Digital presence

Formation Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Formation Bio leadership team

Management profile

Number of profiles

Profiles11 records

Formation Bio subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Formation Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Formation Bio M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Formation Bio

What does Formation Bio do?

Formation Bio acquires clinical-stage drug candidates from pharma companies, universities, and biotech firms and develops them in-house using its proprietary AI-native drug development platform. The company then monetizes these assets through out-licensing deals, milestone payments, royalties, or asset sales to larger pharmaceutical partners. Current pipeline assets include BLKR201 (Phase 1), Sprifermin (Phase 2), Gusacitinib (Phase 3, licensed to Sanofi), RVW101 (Phase 1), and KMR301 (preclinical).

Is Formation Bio a public or private company?

Formation Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Formation Bio founded?

Formation Bio was founded in 2016. It employs 101 to 250 people.

Where is Formation Bio based?

Formation Bio is headquartered in New York, United States, in the North America region.

How does Formation Bio make money?

Two revenue lines are on record. Asset Licensing and Development is the primary driver. The others are asset Sales.

Who are Formation Bio's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, BenevolentAI, Exscientia, Schrödinger, Isomorphic Labs and XtalPi. Owkin is listed as an emerging player. Broad incumbents are Eli Lilly (Lilly Catalyze360 / TuneLab) and Sanofi.

Does Formation Bio have an API?

No public API is recorded for Formation Bio.

What industry is Formation Bio in?

Formation Bio's product category is AI-Driven Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SemaforMedical students should ‘learn the hard way,’ AI startup CEO saysOpenEvidence CEO Daniel Nadler advised medical students to take paper exams and master material despite AI use, citing acute cognitive offloading risks. The startup, which synthesizes medical information with AI, has a $15 billion valuation. Formation Bio CEO Benjamine Liu also spoke on AI's role in pharma.Pulse 2.0Formation Bio Launches $600 Million Drug Development Accelerator FundFormation Bio launched a $600 million drug development accelerator fund to expand its clinical-stage portfolio. The fund aims to acquire 10-15 drug programs over three to five years, with limited partners including foundations and hospitals. Each program will be held in a standalone entity, sharing the company's infrastructure.YahooFormation raises $600 million to fix AI's biotech bottleneckFormation Bio raised $600 million in a drug development accelerator fund to address AI's bottleneck in drug development. The fund will acquire molecules and programs, aiming to cut clinical trial costs by 30-50% through AI and centralization. CEO Ben Liu plans to build a large pharma company without further equity dilution.Pharmaceutical TechnologyFormation Bio launches $600m drug development fundFormation Bio launched a $600m drug development fund to acquire and advance 10-15 drug programmes over three to five years. The fund will source Phase I and II assets from biotech and pharma entities, with capital deployed via a hub-and-spoke model. The company aims to reach major clinical milestones within two to four years of acquisition.WsjIn a Twist, Venture-Backed Biotech Formation Bio Raises Its Own Investment FundFormation Bio, a privately held drug company, raised a $600 million fund to finance its drug development strategy. The company acquires compounds and advances them through clinical trials, housing each program in a newly formed company.citybizFormation Bio Launches $600M Drug Development Fund to Expand Clinical-Stage PipelineFormation Bio launched a $600 million drug development fund to expand its clinical-stage pipeline. The fund will finance acquisitions and development of drug programs, aiming to add 10 to 15 programs over three to five years. The company expects to advance acquired programs toward major clinical milestones within two to four years.Endpoints NewsFormation Bio unveils $600M fund to license and test more drugsFormation Bio, an AI-focused biotech, raised a $600 million investment to license and test more drugs. The company acquires outside assets, develops them, and then hands them off.TechStartupsFormation Bio launches $600M fund to accelerate AI-powered drug developmentFormation Bio launched a $600 million fund to acquire and accelerate AI-powered drug development, targeting 10-15 drug programs over three to five years. The fund will place each program in a separate legal entity, with the company expecting clinical milestones within two to four years.PR NewswireFormation Bio Announces $600 Million Debut Fund to Expand Drug Development CapacityFormation Bio announced a $600 million Drug Development Accelerator Fund to expand its clinical-stage drug portfolio. The fund will support acquiring 10-15 drug programs over 3-5 years, with capital deployed per program's needs. The company expects to partner programs for commercialization after clinical progress.PR NewswireAnirvan Ghosh Joins Formation Bio as SVP, Head of Translational SciencesAnirvan Ghosh joined Formation Bio as SVP, Head of Translational Sciences, bringing experience from Biogen, Roche, and Unity Biotechnology. He will guide which drug candidates the company advances and the evidence each program must generate to progress. The company aims to leverage its AI capabilities to accelerate drug development.